Sclerosing of recurrent lymphangioma using OK-432

J Pediatr Surg. 1995 Aug;30(8):1159-60. doi: 10.1016/0022-3468(95)90011-x.


The authors present two cases of lymphangioma of the cervicofacial region, treated with a new investigational drug in North America, OK-432 (picibanil), a sclerosing agent intralesionally injected. Both patients had been treated surgically and had recurrence of the tumor. Intralesional injection of OK-432 without aspiration was employed for the first patient, and after aspiration in the second patient. A change in consistency of the tumor, manifested by softening, was followed by marked shrinkage. No complication either locally or systemically has occurred during the follow-up period (10 to 16 months). In both cases, satisfactory results were obtained, resulting in definite reduction in size and improvement in cosmetic appearance. The authors recommend OK-432 intralesional injection for surgically challenging lymphangioma. Their results support those of a recent Japanese study using OK-432 as sclerosing therapy for unresectable lymphangioma.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Esthetics
  • Facial Neoplasms / drug therapy
  • Facial Neoplasms / pathology
  • Follow-Up Studies
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / pathology
  • Humans
  • Injections, Intralesional
  • Lymphangioma / drug therapy*
  • Lymphangioma / pathology
  • Lymphangioma, Cystic / drug therapy
  • Lymphangioma, Cystic / pathology
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Picibanil / administration & dosage
  • Picibanil / therapeutic use*
  • Sclerosing Solutions / administration & dosage
  • Sclerosing Solutions / therapeutic use*
  • Sclerotherapy*
  • Suction
  • Tongue Neoplasms / drug therapy
  • Tongue Neoplasms / pathology


  • Antineoplastic Agents
  • Sclerosing Solutions
  • Picibanil